Document is current
Any future updates will be listed below
-
Authors
Byrd, A. S. https://orcid.org/0000-0001-5358-4247
Dina, Y.
Okoh, U. J.
Quartey, Q. Q.
Carmona-Rivera, C. https://orcid.org/0000-0002-7706-1464
Williams, D. W.
Kerns, M. L.
Miller, R. J. https://orcid.org/0000-0002-7662-6136
Petukhova, L.
Naik, H. B.
Barnes, L. A.
Shipman, W. D.
Caffrey, J. A.
Sacks, J. M.
Milner, S. M.
Aliu, O.
Broderick, K. P.
Kim, D.
Liu, H.
Dillen, C. A.
Ahn, R. https://orcid.org/0000-0002-9698-2752
Frew, J. W.
Kaplan, M. J.
Kang, S.
Garza, L. A. https://orcid.org/0000-0002-6547-9695
Miller, L. S.
Alavi, A.
Lowes, M. A.
Okoye, G. A.
- License Information
-
More Information
Article History
Received: 29 October 2018
Accepted: 22 July 2019
First Online: 21 August 2019
Competing Interests
: A.S.B. and G.A.O. are investigators for Eli Lilly. A.S.B. recieved honorarium for speaking at the 77th Annual Society for Investigative Dermatology meeting - AbbVie Sponsored Symposium. J.M.S. is a consultant for Allergen and Co-Founder of LifeSprout, which had no impact or conflicts related to this manuscript. L.S.M. has received grant support from AstraZeneca, MedImmune, Pfizer, Regeneron Pharmaceuticals, Moderna Therapeutics, and Boehringer Ingelheim, and is on the scientific advisory board for Integrated Biotherapeutics, and is a shareholder of Noveome Biotherapeutics, which are all unrelated to the work reported in this manuscript. A.A. received grant funding or honorarium from AbbVie, Galderma, LEO Pharma, Novartis, Sanofi, and Valeant, and hese relationships or funds had no impact or conflicts related to this manuscript. M.A.L. has received consulting honorarium from Abbvie, Incyte, and Xbiotech, but these relationships had no impact on this manuscript. G.A.O. received honorarium from AbbVie for participation on their Hidradenitis Suppurativa Advisory Board. Y.D., U.J.O., Q.Q.Q., C.C.-R., D.W.W., M.L.K., R.J.M., L.P., H.B.N., L.A.B., W.D.S., J.A.C., S.M.M., O.A., K.P.B., D.K., H.L., C.A.D., R.A., J.W.F., M.J.K., S.K., and L.A.G. declare no potential conflicts of interest.
